Sort
21,453 grants matching “tuberculosis”
Mechanism Based Inhibition of M Tuberculosis Enzymes
$666,048John S Blanchard · Albert Einstein College Of Medicine · R01 · FY2009 · AI
Tuberculosis Elimination and Laboratory Cooperative Agreements
$665,970Eric Hueste · Missouri State Dept/ Health & Senior Srv · U52 · FY2014 · PS
Canadian Fluoroscopy Cohort Study: Lifespan Mortality and Incidence Follow-Up
$665,941Lydia B Zablotska · University Of California, San Francisco · R01 · FY2020 · CA
Hybrid trial for Alcohol reduction among people with TB and HIV in India (HATHI)
$665,919Geetanjali Chander · Johns Hopkins University · R01 · FY2020 · AA
Kaiser Washington Vaccine and Treatment Evaluation Unit
$665,827Lisa A Jackson · Kaiser Foundation Research Institute · UM1 · FY2025 · AI
Community Transmission of Tuberculosis Urban Africa
$665,817Christopher C. Whalen · University Of Georgia · R01 · FY2019 · AI
Necrosis in Pulmonary TB granulomas: dynamics, mechanisms, and therapies
$665,784Igor Kramnik · Boston University Medical Campus · R01 · FY2024 · HL
The regulation and functions of Group 1 CD1-restricted T cells
$665,738Chyung-Ru Wang · Northwestern University At Chicago · R01 · FY2023 · AI
Drugs targeting persistent Mycobacterium Tuberculosis
$665,659William Robert Jacobs · Albert Einstein College Of Medicine · R01 · FY2014 · AI
Evolution, transmission, and control of drug-resistant tuberculosis
$665,566Theodore H Cohen · Yale University · R01 · FY2025 · AI
Clinical Trial of Short Course vs. INH for LTBI in Jail
$665,347Mary Castle White · University Of California, San Francisco · U01 · FY2007 · AI
Novel non-invasive antigen detection assay for the diagnosis of active visceral leishmaniasis and to monitor the therapy efficacy of this disease
$665,346Claudia Abeijon · Detectogen, Inc. · R44 · FY2018 · AI
Improving outcomes in HIV-associated opportunistic infections using CNS pharmacokinetics and pharmacodynamics
$665,171Melanie Rae Nicol · University Of Minnesota · R01 · FY2024 · NS
HIV, gestational diabetes and TB in pregnancy
$665,122Jyoti S Mathad · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · AI
I TITRATE PC: An Implementation based Community Health Worker Intervention to address Disparities in Palliative Care
$665,032Fabian M Johnston · Wake Forest University Health Sciences · R01 · FY2025 · MD
Bone health in perinatally HIV-infected South African children on antiretrovirals
$664,924Stephen M Arpadi · Columbia University Health Sciences · R01 · FY2014 · HD
NK cell-mediated regulation of T cell immunity in TB/HIV co-infection
$664,621Cheryl Liane Day · Emory University · R01 · FY2014 · AI
Mycobacterium tuberculosis antigen diversity
$664,613Joel D. Ernst · New York University School Of Medicine · R01 · FY2010 · AI
Optimizing Detection and Interventions Against Rare Pre-existing Drug Resistance Mutations
$664,591Lawrence Kwong · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · HG
Optimizing Detection and Interventions Against Rare Pre-existing Drug Resistance Mutations
$664,591Lawrence Kwong · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · HG
Optimizing Detection and Interventions Against Rare Pre-existing Drug Resistance Mutations
$664,591Lawrence Kwong · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · HG
Antimicrobial evaluation and development
$664,543Kim Lewis · Northeastern University · P01 · FY2020 · AI
Tuberculosis epidemiology and novel transmission routes in rural Tanzania
$664,540Philip C Hopewell · University Of California, San Francisco · U01 · FY2010 · AI
Novel Methods to Inform HIV/TB Clinical Trial Development
$664,504Rochelle P Walensky · Massachusetts General Hospital · R01 · FY2011 · AI
Innovative Approaches to Tuberculosis Control
$664,048Johns Hopkins University · U19 · FY2005 · AI